Most Read Articles
Jairia Dela Cruz, 2 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim, 27 Nov 2019
The current standard of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour with a rapid disease course, consists of maximum safe surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the evidence and shared their clinical experience on the use of tumour treating fields (TTFields), a novel treatment modality for GBM. 
Stephen Padilla, 2 days ago
There appears to be no significant survival difference between first-line immune checkpoint inhibitor (ICI) and carboplatin-based chemotherapy in cisplatin-ineligible metastatic urothelial carcinoma patients, according to a Taiwan study presented at the recent 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).

Akt/mTOR, STAT3, ERK, PD-L1 expression linked to DFSP development, progression

21 Oct 2018

Local recurrence or metastasis of dermatofibrosarcoma protuberans (DFSP) may be predicted by complex factors beyond fibrosarcomatous subtype, according to a recent study.

Moreover, development and/or progression of DFSP appear to be associated with expression of protein kinase B (Akt)/mammalian target of rapamycin (mTOR), signal transducer and activator of transcription 3 (STAT3), extracellular signal regulated kinase (ERK) and programmed death ligand 1 (PD-L1).

Nine recurrent DFSPs had larger tumour size, deeper invasion beyond the subcutis and more diverse histologic subtype compared with 35 noncurrent DFSPs. The fibrosarcomatous subtype showed a high cyclin D1–positive index and frequent mitotic figures.

Two metastatic DFSPs (one each of the fibrosarcomatous and myxoid subtypes) revealed four and 11 instances of local recurrence, respectively. These DFSPs also demonstrated larger tumour size, deeper invasion beyond the subcutis and high expression of cyclin D1.

Expression of Akt/mTOR, STAT3, ERK and PD-L1 was none or low in the primary skin lesions and high in the corresponding metastatic sites. DFSP had more frequent expression of Akt/mTOR and ERK than did dermatofibroma.

In this study, the authors performed clinicopathologic and immunohistochemical analyses for 44 DFSPs having wide local excision and 92 dermatofibromas as controls to determine the features and key factors for adverse outcome in DFSP, as well as the implication of expression of Akt/mTOR, STAT3, ERK, cyclin D1 and PD-L1.

The study was limited by the lack of data on patients prior to hospital evaluation.

“Little is known regarding oncoproteins other than platelet-derived growth factor subunit B in DFSP. Moreover, the risk factors for worse prognosis are controversial,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 2 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim, 27 Nov 2019
The current standard of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour with a rapid disease course, consists of maximum safe surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the evidence and shared their clinical experience on the use of tumour treating fields (TTFields), a novel treatment modality for GBM. 
Stephen Padilla, 2 days ago
There appears to be no significant survival difference between first-line immune checkpoint inhibitor (ICI) and carboplatin-based chemotherapy in cisplatin-ineligible metastatic urothelial carcinoma patients, according to a Taiwan study presented at the recent 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).